Why the study?
CYP2C19 genotype influences clopidogrel bioactivation, with intermediate and poor metabolizers facing reduced platelet inhibition and elevated cardiovascular risk, prompting an updated clinical guideline.
Does CYP2C19 genotype-guided antiplatelet therapy reduce major adverse cardiovascular and cerebrovascular events compared to conventional clopidogrel therapy in patients with cardiovascular or neurovascular indications?
Does CYP2C19 genotype-guided antiplatelet therapy reduce major adverse cardiovascular and cerebrovascular events compared to conventional clopidogrel therapy in patients with cardiovascular or neurovascular indications?
Answers are grounded in this paper and cite their sources.
This 2022 CPIC guideline update upgrades the recommendation to avoid clopidogrel in CYP2C19 intermediate metabolizers undergoing PCI/ACS to 'strong' and expands CYP2C19 genotype-guided antiplatelet recommendations to neurovascular disease (stroke/TIA).
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events. This guideline is an update to the 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of clopidogrel based on CYP2C19 genotype and includes expanded indications for CYP2C19 genotype-guided antiplatelet therapy, increased strength of recommendation for CYP2C19 intermediate metabolizers, updated CYP2C19 genotype to phenotype translation, and evidence from an expanded literature review (updates at www.cpicpgx.org).
No takes yet. Share an insight, caveat, or question.
A 2022 study studied Cardiovascular and neurovascular indications requiring clopidogrel antiplatelet therapy (including acute coronary syndromes, percutaneous coronary intervention, peripheral arterial disease, acute ischemic stroke, or transient ischemic attack). CYP2C19 genotype-guided antiplatelet therapy (prasugrel or ticagrelor in CYP2C19 intermediate and poor metabolizers; standard-dose clopidogrel in normal metabolizers) vs. Standard non-genotype-guided clopidogrel therapy (75 mg/day) was evaluated on Major adverse cardiovascular and cerebrovascular events (MACE, stent thrombosis, ischemic stroke).
Synapse has enriched 10 related papers. Consider them for comparative context: